Upside case
Bull case
$33-81.7%
The bull case prices MASI at 6x on FY1 earnings, assuming continued execution and no meaningful deceleration in the core business.
Analysis OverviewBuyUpdated Jun 18, 2026
Masimo Corporation (MASI) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
23
analysts
14 bullish · 0 bearish · 23 covering MASI
Strong Buy
0
Buy
14
Hold
9
Sell
0
Strong Sell
0
Consensus Target
$180
+0.0% vs today
Scenario Range
$16 – $33
Model bear to bull value window
Coverage
23
Published analyst ratings
Valuation Context
32.7x
Forward P/E · Market cap $9.4B
MASI price targets
Three scenarios for where MASI stock could go
Current
~$180
Confidence
44 / 100
Updated
Jun 18, 2026
Where we are now
Current · $180
Bear
$16
Base
$25
Bull
$33
Market caseClosest to today
Base case
$25-86.1%
At 5x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
Stress case
Bear case
$16-91.2%
If investor confidence fades or macro conditions deteriorate, a 30x multiple contraction could push MASI down roughly 91% from where it trades now.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Masimo Corporation
MASI · NASDAQHealthcareMedical - Instruments & SuppliesJanuary year-end
Masimo is a medical technology company that develops noninvasive patient monitoring systems and hospital automation solutions. It generates revenue primarily from sales of its pulse oximetry devices and monitoring technologies—including its flagship Masimo SET and Rainbow platforms—alongside recurring revenue from sensors and accessories. The company's competitive advantage lies in its proprietary signal extraction technology that provides more accurate readings during patient motion and low blood flow conditions, which has become a clinical standard in many hospitals.
Market Cap
$9.4B
Revenue TTM
$1.6B
Net Income TTM
$76M
Net Margin
4.9%
MASI Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
83%Exceptional
12 quarters tracked
Revenue Beat Rate
75%Exceptional
vs consensus estimates
Avg EPS Surprise
+1.4%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 3 of 4Q3 2025
EPS
$1.33/$1.23
Revenue
$371M/$369M
Q4 2025
EPS
$1.32/$1.19
Revenue
$372M/$408M
Q1 2026
EPS
$0.18/$1.48
Revenue
$413M/$408M
Q2 2026
EPS
$1.43/$1.41
Revenue
$400M/$399M
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $1.33/$1.23 | +8.1% | $371M/$369M | +0.5% |
| Q4 2025 | $1.32/$1.19 | +10.9% | $372M/$408M | -8.9% |
| Q1 2026 | $0.18/$1.48 | -87.8% | $413M/$408M | +1.1% |
| Q2 2026 | $1.43/$1.41 | +1.4% | $400M/$399M | +0.2% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$1.6B
+3.1% YoY
FY2
$1.7B
+3.6% YoY
EPS Outlook
FY1
$1.64
+13.3% YoY
FY2
$1.39
-15.4% YoY
Trailing FCF (TTM)$211M
FCF Margin: 13.6%
Next Earnings
August 4, 2026
Expected EPS
$1.43
Expected Revenue
$399M
MASI beat EPS estimates in 3 of 4 tracked quarters. A strong delivery record supports forward estimate credibility.
MASI Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $1.5B
Product Mix
Latest annual revenue by segment or product family
Health Care Segment
100.0%
+9.2% YoY
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
UNITED STATES
62.6%
-15.2% YoY
Tap, hover, or focus a slice to inspect segment detail.
Health Care Segment is the largest disclosed segment at 100.0% of FY 2025 revenue, up 9.2% YoY.
UNITED STATES is the largest reported region at 62.6%, down 15.2% YoY.
MASI Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Expensive versus peers
Fair value est. $92 — implies -48.7% from today's price.
Premium to Fair Value
48.7%
above fair value
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
MASI
-64.3x
vs
S&P 500
24.4x
363% discount
vs Healthcare Trailing P/E
MASI
-64.3x
vs
Healthcare
22.1x
391% discount
vs MASI 5Y Avg P/E
Today
-64.3x
vs
5Y Average
69.4x
193% discount
Forward PE
32.7x
S&P 500
18.8x
+74%
Healthcare
18.3x
+79%
5Y Avg
—
—
Trailing PE
-64.3x
S&P 500
24.4x
-363%
Healthcare
22.1x
-391%
5Y Avg
69.4x
-193%
PEG Ratio
—
S&P 500
1.66x
—
Healthcare
1.59x
—
5Y Avg
—
—
EV/EBITDA
28.0x
S&P 500
15.2x
+84%
Healthcare
14.2x
+97%
5Y Avg
32.3x
-13%
Price/FCF
47.6x
S&P 500
20.7x
+130%
Healthcare
18.5x
+157%
5Y Avg
57.0x
-16%
Price/Sales
6.2x
S&P 500
3.1x
+100%
Healthcare
2.6x
+134%
5Y Avg
5.9x
+4%
Dividend Yield
—
S&P 500
1.91%
—
Healthcare
1.50%
—
5Y Avg
—
—
| Metric | MASI | S&P 500 | Healthcare | 5Y Avg MASI |
|---|---|---|---|---|
| Forward PE | 32.7x | 18.8x+74% | 18.3x+79% | — |
| Trailing PE | -64.3x | 24.4x-363% | 22.1x-391% | 69.4x-193% |
| PEG Ratio | — | 1.66x | 1.59x | — |
| EV/EBITDA | 28.0x | 15.2x+84% | 14.2x+97% | 32.3x-13% |
| Price/FCF | 47.6x | 20.7x+130% | 18.5x+157% | 57.0x-16% |
| Price/Sales | 6.2x | 3.1x+100% | 2.6x+134% | 5.9x |
| Dividend Yield | — | 1.91% | 1.50% | — |
MASI trades above S&P 500 benchmarks on 4 of 5 measured multiples — commands a broad premium across most valuation dimensions.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolMASI Financial Health
Verdict
Strong
MASI generates $211M in free cash flow at a 13.6% margin — 16.5% ROIC signals a durable competitive advantage · returns 3.9% of market cap to shareholders annually.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$1.6B
Revenue Growth
TTM vs prior year
-14.4%
Gross Margin
Gross profit as a share of revenue
61.7%
Operating Margin
Operating income divided by revenue
19.9%
Net Margin
Net income divided by revenue
4.9%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$1.45
Free Cash Flow (TTM)
Cash generation after capex
$211M
FCF Margin
FCF as share of revenue — the primary cash quality signal
13.6%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
16.5%
ROA
Return on assets, trailing twelve months
4.0%
Cash & Equivalents
Liquid assets on the balance sheet
$152M
Net Debt
Total debt minus cash
$407M
Debt Serviceability
Net debt as a multiple of annual free cash flow
1.9× FCF
~1.9 years to full repayment at current FCF run-rate
ROE
Return on equity, trailing twelve months
9.1%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
3.9%
Dividend
—
Buyback
3.9%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$364M
Dividend / Share
Annualized trailing dividend per share
—
Payout Ratio
Share of earnings distributed as dividends
—
Shares Outstanding
Declining as buybacks retire shares
52M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageMASI Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated June 18, 2026
High Risk
Acquisition Integration
Masimo's acquisition by Danaher introduces risks related to integration challenges, potential cultural clashes, and operational disruptions.
High Risk
Stock Delisting
Masimo common stock has ceased trading on Nasdaq, creating liquidity risks and uncertainty for shareholders.
Medium
Valuation Risks
Analysts highlight potential valuation de-rating risks, with some advising selling due to unexpected positive announcements.
Medium
Regulatory Scrutiny
As a medical device company, Masimo faces risks from regulatory changes or delays in product approvals.
Lower
Market Volatility
Geopolitical and news factors may introduce volatility in Masimo's stock performance despite strong fundamentals.
Lower
Technology Adoption
Slower-than-expected adoption of Masimo's non-invasive monitoring technologies could impact revenue growth.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why MASI Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated June 18, 2026
Innovative medical technology
Masimo develops and manufactures innovative noninvasive patient monitoring technologies and medical devices, positioning it as a leader in healthcare innovation.
Strong earnings growth
Wall Street expects Masimo to deliver $1.41 per share for Q1 2026, representing a 3.68% growth compared to the previous year, indicating strong financial performance.
Acquisition by Danaher
Masimo's acquisition by Danaher is seen as a bullish catalyst, with the deal set to close imminently and likely to drive investor interest and market outperformance.
Bullish analyst sentiment
Multiple bullish theses from sources like Valueinvestorsclub.com and HatedMoats's Substack highlight Masimo's potential, reinforcing positive analyst sentiment.
Expanding product portfolio
Masimo's development of patient monitoring devices and consumer electronics, including the SafetyNet monitoring system, showcases its diversified and expanding product offerings.
Healthcare sector strength
Operating in the Medical Devices sector, Masimo benefits from the robust and growing healthcare industry, providing a stable and high-demand market for its products.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
MASI Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$179.95
52W Range Position
100%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$125.94
+42.9% from the low
52-Week High
$179.99
-0.0% from the high
1 Month
+0.64%
3 Month
+2.20%
YTD
+41.2%
1 Year
+10.6%
3Y CAGR
+3.1%
5Y CAGR
-5.6%
10Y CAGR
+13.3%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
MASI vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
32.7x
vs 17.2x median
+90% above peer median
Revenue Growth
+3.1%
vs +8.9% median
-65% below peer median
Net Margin
4.9%
vs 7.7% median
-36% below peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
MAS MASI Masimo Corporation | $9.4B | 32.7x | +3.1% | 4.9% | Buy | +0.0% |
POD PODD Insulet Corporation | $10.2B | 22.5x | +13.5% | 10.4% | Buy | +53.1% |
HOL HOLX Hologic, Inc. | $17.0B | 17.2x | +4.3% | 13.2% | Hold | +3.5% |
NVC NVCR NovoCure Limited | $1.6B | — | +9.0% | -25.7% | Buy | +131.1% |
ITG ITGR Integer Holdings Corporation | $3.1B | 15.0x | +8.9% | 7.7% | Buy | +18.7% |
ICU ICUI ICU Medical, Inc. | $3.5B | 17.2x | +5.2% | 2.1% | Buy | +17.9% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
MASI Dividend and Capital Return
MASI returns 3.9% annually — null% through dividends and 3.9% through buybacks.
Dividend UnknownFCF Unknown
Total Shareholder Yield
3.9%
Dividend + buyback return per year
Buyback Yield
3.9%
Dividend Yield
—
Payout Ratio
—
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$0.00
Growth Streak
Consecutive years of dividend increases
0Y
3Y Div CAGR
—
5Y Div CAGR
—
Ex-Dividend Date
—
Payment Cadence
Annual
0 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$364M
Estimated Shares Retired
2M
Approx. Share Reduction
3.9%
Shares Outstanding
Current diluted share count from the screening snapshot
52M
At 3.9%/year, buybacks mechanically lift EPS even with flat earnings — each remaining share represents a slightly larger piece of the company.
| Year | Div / Share | YoY Grw | BB Yield | Total Yield |
|---|---|---|---|---|
| 2012 | $1.00 | — | 2.1% | 6.8% |
| 2010 | $2.75 | — | 0.0% | 9.2% |
FAQ
7 questionsMASI Investor Questions
Common questions answered from live analyst data and company financials.
01Is Masimo Corporation (MASI) stock a buy or sell in 2026?
Masimo Corporation (MASI) is rated Buy by Wall Street analysts as of 2026. Of 23 analysts covering the stock, 14 rate it Buy or Strong Buy, 9 rate it Hold, and 0 rate it Sell or Strong Sell. The consensus 12-month price target is $180, implying +0.0% from the current price of $180. The bear case scenario is $16 and the bull case is $33.
02What is the MASI stock price target for 2026?
The Wall Street consensus price target for MASI is $180 based on 23 analyst estimates. The high-end target is $180 (+0.0% from today), and the low-end target is $180 (+0.0%). The base case model target is $25.
03Is Masimo Corporation (MASI) stock overvalued in 2026?
MASI trades at 32.7x times forward earnings. The stock currently trades at a discount to the broader market. Based on current multiples versus the peer group, the relative model signals expensive versus peers. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
04What are the main risks for Masimo Corporation (MASI) stock in 2026?
The primary risks for MASI in 2026 are: (1) Acquisition Integration — Masimo's acquisition by Danaher introduces risks related to integration challenges, potential cultural clashes, and operational disruptions. (2) Stock Delisting — Masimo common stock has ceased trading on Nasdaq, creating liquidity risks and uncertainty for shareholders. (3) Valuation Risks — Analysts highlight potential valuation de-rating risks, with some advising selling due to unexpected positive announcements. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Masimo Corporation's revenue and earnings forecast?
Analyst consensus estimates MASI will report consensus revenue of $1.6B (+3.1% year-over-year) and EPS of $1.64 (+13.3% year-over-year) for the upcoming fiscal year. The following year, analysts project $1.7B in revenue.
06When does Masimo Corporation (MASI) report its next earnings?
Masimo Corporation is expected to report its next earnings on approximately 2026-08-04. Consensus expects EPS of $1.43 and revenue of $399M. Over recent quarters, MASI has beaten EPS estimates 83% of the time.
07How much free cash flow does Masimo Corporation generate?
Masimo Corporation (MASI) generated $211M in free cash flow over the trailing twelve months — a free cash flow margin of 13.6%. MASI returns capital to shareholders through and share repurchases ($364M TTM).